Search the Studies

159 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
001730-CPhase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination with Immunotherapy Vaccine PRGN-2009 in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerRecruitment has not started18-120 YearsNCI Squamous Carcinoma
001572-CA Phase II Study of Bevacizumab in Adults with Recurrent Respiratory Papillomatosis (RRP)Participants currently recruited/enrolled18-120 YearsNCI Gland Squamous
001564-CA Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 alone or in Combination with PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaRecruitment has not started18-120 YearsNCI Squamous Carcinoma
001547-CA First-in-Human Phase I Trial with Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and CarcinomasParticipants currently recruited/enrolled18-120 YearsNCI Gland Carcinoma
001545-CA Phase Ib/II Multicenter Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASRecruitment has not started18-120 YearsNCI Squamous Carcinoma
001536-CPhase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 with Pembrolizumab before Standard Treatment in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal CancerParticipants currently recruited/enrolled18-120 YearsNCI Squamous Carcinoma
001535-CA Phase II Study of Sacituzumab Govitecan with or without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile CancerRecruitment has not started18-120 YearsNCI Squamous Carcinoma
001533-CA Phase II Multicenter Study of Enfortumab Vedotin with or without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)Recruitment has not started18-120 YearsNCI Squamous Carcinoma
001109-CDefining the Natural History of Squamous Cell Carcinoma in Fanconi AnemiaParticipants currently recruited/enrolled8-125 YearsNCI Squamous Carcinoma
001004-CA Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature(R) StatusParticipants currently recruited/enrolled18-120 YearsNCI Gland Carcinoma
000491-CTissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)Participants currently recruited/enrolled18-125 YearsNCI Gland Carcinoma
000462-CPhase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Squamous Carcinoma
21-DC-0002Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck CancerParticipants currently recruited/enrolled18-100 YearsNIDCDSquamous Carcinoma
20-C-0097A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Gland Carcinoma
20-C-0024A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.Completed Study; data analyses ongoing18-120 YearsNCI Squamous Carcinoma
19-C-0041Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)Completed Study; data analyses ongoing18-125 YearsNCI Squamous Carcinoma
19-C-0016Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid TumorsParticipants currently recruited/enrolled0-125 YearsNCI Squamous Carcinoma
17-DC-0138Observational Study of Hearing Loss and the Effects of Statin Drugs in Head and Neck Squamous Cell Carcinoma Patients Treated with Cisplatin ChemoradiationCompleted Study; data analyses ongoing18-125 YearsNIDCDSquamous Carcinoma
17-C-0066A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based ChemotherapyParticipants currently recruited/enrolled18-125 YearsNCI Gland Carcinoma
16-C-0154A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated CancersParticipants currently recruited/enrolled18-120 YearsNCI Squamous Carcinoma
15-D-0129Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals with Irradiation-Induced Parotid Salivary Hypofunction.Participants currently recruited/enrolled18-125 YearsNIDCRGland Squamous
14-C-0104A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative RegimenParticipants currently recruited/enrolled18-72 YearsNCI Squamous Carcinoma
12-C-0178Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid CarcinomaParticipants currently recruited/enrolled0-125 YearsNCI Gland Carcinoma
08-EI-0102Screening Protocol for the Evaluation and Diagnosis of Potential Research ParticipantsParticipants currently recruited/enrolled2-100 YearsNEI Lacrimal Gland
001886-CA Phase 1 Study of APG-1252 (pelcitoclax) and cobimetinib in recurrent ovarian and endometrial cancersParticipants currently recruited/enrolled18-120 YearsNCI Carcinoma
001833-DSjogren's Team for Accelerating Medicines Partnership (STAMP)Participants currently recruited/enrolled18-79 YearsNIDCRGland
001808-CMAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab after First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial CancerParticipants currently recruited/enrolled18-120 YearsNCI Carcinoma
001733-CA Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal CarcinomaParticipants currently recruited/enrolled18-100 YearsNCI Carcinoma
001715-CA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-AssociRecruitment has not started12-120 YearsNCI Gland
001617-EOBServation of Environment and ReproductiVe Endocrine effects study (OBSERVE study)Participants currently recruited/enrolled8-99 YearsNIEHSGland
001600-CPhase 2 Study Evaluating the Functional Status of the Adrenal Glands with [68Ga]Ga-PentixaFor in Hyperaldosteronism and HypercortisolismRecruitment has not started18-120 YearsNCI Gland
001583-CA Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Completed Study; data analyses ongoing18-120 YearsNCI Carcinoma
001578-CA Phase 1/2 Study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsParticipants currently recruited/enrolled3-100 YearsNCI Carcinoma
001559-CA Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitment has not started18-120 YearsNCI Carcinoma
001557-CPhase I/II Trial of Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination with HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants with Advanced or Metastatic Endometrial Cancer (EC)Recruitment has not started18-120 YearsNCI Carcinoma
001552-CPhase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base TumorsParticipants currently recruited/enrolled18-120 YearsNCI Carcinoma
001548-CA Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination with Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects with Biliary Tract Carcinoma (BTC)Recruitment has not started0-120 YearsNCI Carcinoma
001523-CA Phase II Study of Lurbinectedin with or without Avelumab in Small Cell Carcinoma of the Bladder (LASER)Participants currently recruited/enrolled18-120 YearsNCI Carcinoma
001099-CA Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors thatParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
001085-DPhase 2 Study of the PTH-Independent Effects of Encaleret on Mineral Homeostasis in Subjects with Post-Surgical Hypoparathyroidism (PSH)Participants currently recruited/enrolled18-100 YearsNIDCRGland
001043-IEvaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil DisordersParticipants currently recruited/enrolled0-99 YearsNIAIDGland
000954-CA Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing CancerNo longer recruiting/follow-up only18-120 YearsNCI Carcinoma
000930-CA Phase 1b/2 Study of HCW9218, a Bifunctional TGF-beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic CancerParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
000826-CAn Open Label, Randomized, Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination with Sorafenib or Sorafenib Alone, in TKI Na(SqrRoot) ve Participants with Previously Treated Advanced Hepatocellular Carcinoma (HCC) anRecruitment has not started18-125 YearsNCI Carcinoma
000740-CHA Phase 3 Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal HyperplasiaEnrolling by Invitation18-99 YearsNICHDGland
000666-CA Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)Participants currently recruited/enrolled18-100 YearsNCI Carcinoma
000611-CA Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI Gland
000596-CPhase II Study of Olaparib in Subjects with Advanced Pancreatic Acinar Cell CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
000580-CA Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2(alpha) Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell CarcinomParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
000569-CClinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for ProstatectomyParticipants currently recruited/enrolled18-125 YearsNCI Gland
000520-CPhase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with or without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
000473-CA Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic CholangiocarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
000354-CPhase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
000344-DKNatural History Study of Parathyroid DisordersParticipants currently recruited/enrolled0-100 YearsNIDDKGland
000317-CA Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
000310-CHA Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy for Congenital Adrenal Hyperplasia through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human Participants currently recruited/enrolled18-99 YearsNICHDGland
000303-CA Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide Vs. Temozolomide and Olaparib For Advanced Pheochromocytoma And ParagangliomaParticipants currently recruited/enrolled18-125 YearsNCI Gland
000302-CA Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
000254-CA Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)Participants currently recruited/enrolled18-125 YearsNCI Carcinoma
000237-CPhase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary CancerParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
000080-C18F-DCFPyL PET/CT in Hepatocellular CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
000045-CA Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and other KK-LC-1 Positive Epithelial CancersParticipants currently recruited/enrolled18-120 YearsNCI Carcinoma
22-C-0005Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung CancerParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
22-C-0004A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell CancerParticipants currently recruited/enrolled12-120 YearsNCI Carcinoma
21-C-0030Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)Participants currently recruited/enrolled18-125 YearsNCI Carcinoma
21-C-0023A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies with or without HIVParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
21-C-0012Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
21-C-0007A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon CancersParticipants currently recruited/enrolled18-120 YearsNCI Squamous
20-N-0048Corticotrophin-Releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing's DiseaseRecruitment has not started8-125 YearsNINDSGland
20-N-0019The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's DiseaseParticipants currently recruited/enrolled18-125 YearsNINDSGland
20-D-0131Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome; a Phase Ib-IIa Placebo-controlled Clinical Trial and Associated Mechanistic StudiesParticipants currently recruited/enrolled18-75 YearsNIDCRGland
20-D-0094Transmissibility and Viral Load of SARS-CoV-2 Through Oral SecretionsCompleted Study; data analyses ongoing18-125 YearsNIDCRGland
20-CH-0126Data Collection Study of Pediatric and Adolescent Gynecology ConditionsParticipants currently recruited/enrolled0-125 YearsNICHDGland
20-CC-0039A Feasibility Study to Evaluate the Combination of Electromagnetic Tracking and Optical Imaging with Indocyanine Green (ICG) for Hepatic BiopsiesEnrolling by Invitation18-100 YearsCC Carcinoma
20-C-0155Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination with BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) with CV301 TRICOM in Advanced Solid Tumors (STAT)Completed Study; data analyses ongoing18-120 YearsNCI Squamous
20-C-0149Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
20-C-0142A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects with Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
20-C-0051Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology StudiesEnrolling by Invitation18-120 YearsNCI Squamous
20-C-0045Phase I/II Trial of Combination Immunotherapy in Subjects with Advanced HPV Associated MalignanciesNo longer recruiting/follow-up only18-125 YearsNCI Squamous
20-C-0022Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)Completed Study; data analyses ongoing18-125 YearsNCI Carcinoma
20-C-0013Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersNo longer recruiting/follow-up only18-125 YearsNCI Carcinoma
20-C-0012A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
20-C-0009Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung CancerNo longer recruiting/follow-up only18-125 YearsNCI Carcinoma
20-C-0006A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)Participants currently recruited/enrolled18-125 YearsNCI Carcinoma
19-DK-0066The Evaluation and Management of Endocrine-Related Conditions and PhysiologyParticipants currently recruited/enrolled18-90 YearsNIDDKGland
19-CH-0051Long-Term Follow-UP of Survivors of Pediatric Cushing DiseaseParticipants currently recruited/enrolled2-90 YearsNICHDGland
19-CH-0020A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children with Classic 21-Hydroxylase DeficiencyParticipants currently recruited/enrolled2-9 YearsNICHDGland
19-C-0137A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)Participants currently recruited/enrolled18-125 YearsNCI Carcinoma
19-C-0129A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal CarcinomatosisNo longer recruiting/follow-up only18-125 YearsNCI Carcinoma
19-C-0104A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI Gland
19-C-0094A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)Participants currently recruited/enrolled18-125 YearsNCI Carcinoma
19-C-0039Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal CancersCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
19-C-0033Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic CancersCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
19-C-0023A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair DefectsParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
18-N-0133Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal SurgeryParticipants currently recruited/enrolled18-85 YearsNINDSGland
18-H-0012A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell CarcinomaNo longer recruiting/follow-up only18-75 YearsNHLBICarcinoma
18-DK-0091Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral AgentsParticipants currently recruited/enrolled18-120 YearsNIDDKCarcinoma
18-D-0121Natural History of Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy ControlsParticipants currently recruited/enrolled18-100 YearsNIDCRGland
18-CH-0031Clinical and Molecular Characteristics of Primary Aldosteronism in BlacksClinical hold/Recruitment or enrollment suspended7-70 YearsNIDDKGland
18-C-0147Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid TumorsParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
18-C-0138An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.No longer recruiting/follow-up only18-125 YearsNCI Carcinoma
18-C-0110Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell CancersParticipants currently recruited/enrolled18-99 YearsNCI Carcinoma
18-C-0062Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare TumorsCompleted Study; data analyses ongoing2-30 YearsNCI Carcinoma
18-C-0034A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
18-C-0024A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the LiverParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
18-C-0008Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus ObservationNo longer recruiting/follow-up only18-125 YearsNCI Carcinoma
17-C-0157A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)Completed Study; data analyses ongoing18-125 YearsNCI Carcinoma
17-C-0140Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural MesotheliomasCompleted Study; data analyses ongoing18-99 YearsNCI Carcinoma
17-C-010918F-DCFPyL PET/CT in High Risk and Recurrent Prostate CancerEnrolling by Invitation18-125 YearsNCI Gland
17-C-0092A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal CancerCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
17-C-0087Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaParticipants currently recruited/enrolled18-125 YearsNCI Gland
17-C-0086An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell CarcinomaNo longer recruiting/follow-up only18-125 YearsNCI Carcinoma
17-C-0061Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerCompleted Study; data analyses ongoing18-125 YearsNCI Gland
17-C-0011Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron(R) (Peginterferon alfa-2b) and Actimmune(R) (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
16-DK-0125Evaluation of Adults with Endocrine-Related ConditionsParticipants currently recruited/enrolled18-100 YearsNIDDKGland
16-CH-0113Evaluation of Children with Endocrine and Metabolic-Related ConditionsParticipants currently recruited/enrolled0-100 YearsNICHDGland
16-C-0135A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)Completed Study; data analyses ongoing18-125 YearsNCI Carcinoma
16-C-0128A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
16-C-0121A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
16-C-0107A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate CancersParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
15-EI-0202Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated with Age-Related Macular DegenerationCompleted Study; data analyses ongoing55-100 YearsNEI Gland
15-D-0051Characterization of Diseases with Salivary Gland InvolvementParticipants currently recruited/enrolled4-100 YearsNIDCRGland
15-C-0160A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary TumorsNo longer recruiting/follow-up only18-125 YearsNCI Carcinoma
15-C-0157Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
15-C-0150A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell CancersNo longer recruiting/follow-up only18-125 YearsNCI Carcinoma
15-C-0099A Phase 1, Open-Label, Dose-Escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine TumorsCompleted Study; data analyses ongoing18-100 YearsNCI Carcinoma
15-AR-0144Studies of Dermatologic Diseases-Biospecimen Acquisition ProtocolParticipants currently recruited/enrolled0-100 YearsNIAMSCarcinoma
14-C-0037A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
13-C-0118A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and LymphomasCompleted Study; data analyses ongoing18-120 YearsNCI Carcinoma
12-E-0050The Role of Gonadotropin Pulsations in the Regulation of Puberty and FertilityParticipants currently recruited/enrolled14-125 YearsNIEHSGland
12-C-0205A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
12-C-0118A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic ChemotherapyNo longer recruiting/follow-up only18-100 YearsNCI Carcinoma
11-D-0172The Pathogenesis and Natural History of Sjogren's DiseaseParticipants currently recruited/enrolled16-100 YearsNIDCRGland
11-CH-0078Evaluation of Cortisol Resistance in Young Endurance-Trained and Elderly MenCompleted Study; data analyses ongoing18-30 YearsNICHDGland
11-CC-0152The Natural History of Liver Disease in a Cohort of Participants with Hepatitis B and/or Hepatitis C with or without HIV InfectionCompleted Study; data analyses ongoing18-99 YearsCC Carcinoma
11-C-0140A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
11-C-0096Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesNo longer recruiting/follow-up only18-125 YearsNCI Carcinoma
10-C-0166A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of PembrolizumabParticipants currently recruited/enrolled18-72 YearsNCI Carcinoma
10-C-0114A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell CancerCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
09-C-0242Prospective Comprehensive Molecular Analysis of Endocrine NeoplasmsParticipants currently recruited/enrolled4-125 YearsNCI Gland
09-C-0161Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch StudiesEnrolling by Invitation18-125 YearsNCI Carcinoma
08-H-0186Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with BortezomibCompleted Study; data analyses ongoing18-70 YearsNHLBICarcinoma
07-H-0005Pilot Study of Topical Dexamethasone 0.01% Solution for Prevention of Oral Chronic Graft Versus Host DiseaseCompleted Study; data analyses ongoing12-110 YearsNHLBIGland
07-D-0016Effects of PTH Replacement on Bone in HypoparathyroidismCompleted Study; data analyses ongoing18-70 YearsNIDCRGland
07-CH-0008Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) SecretionCompleted Study; data analyses ongoing18-85 YearsNICHDGland
07-C-0121Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC)Completed Study; data analyses ongoing18-125 YearsNCI Carcinoma
05-CC-0091Electromagnetic Tracking of Devices During Interventional ProceduresEnrolling by Invitation18-120 YearsCC Carcinoma
04-C-0102Hematologic Malignancy Biology StudyEnrolling by Invitation1-75 YearsNCI Gland
02-C-0064Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation TherapyEnrolling by Invitation18-125 YearsNCI Carcinoma
01-DC-0228Clinical and Molecular Analysis of Enlarged Vestibular AqueductsCompleted Study; data analyses ongoing0-99 YearsNIDCDGland
00-CH-0160Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical TissueCompleted Study; data analyses ongoing3-70 YearsNICHDGland
00-CH-0093Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and ParagangliomaParticipants currently recruited/enrolled3-120 YearsNICHDGland
00-C-0078Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer or Normal VolunteersParticipants currently recruited/enrolled18-125 YearsNCI Carcinoma
97-CH-0076A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related DisordersParticipants currently recruited/enrolled3-70 YearsNICHDGland
95-CH-0059Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related ConditionsCompleted Study; data analyses ongoing3-70 YearsNICHDGland
93-I-0063Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T CellsParticipants currently recruited/enrolled0-99 YearsNIAIDGland
89-C-0086Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersParticipants currently recruited/enrolled2-125 YearsNCI Carcinoma
79-C-0111The Treatment of Stage I and II Carcinoma of the Breast with Mastectomy and Axillary Dissection vs. Excisional Biopsy Axillary Dissection, and Definitive IrradiationCompleted Study; data analyses ongoing18-125 YearsNCI Carcinoma
78-HG-0093Use of Cysteamine in the Treatment of CystinosisParticipants currently recruited/enrolled0-115 YearsNHGRIGland